



ajanta pharma limited

20th January, 2011

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001.

AJANTA HOUSE
Charkop, Kandivli (W),
MUMBAI - 400 067. INDIA
Tel. : (+91)22-6606 1000
Fax : (+91)22-6606 1200 / 300
E-mail : info@ajantapharma.com
Website : www.ajantapharma.com

Dear Sir,


Re: Clause 41
Scrip Code: BSE – AJANTAPH 532331
NSE – AJANTPHARM EQ

Pursuant to Clause 41 of the Listing Agreement, we are enclosing herewith Unaudited Financial Results for the third quarter ended 31st December, 2010 duly signed by the Managing Director. These results were approved by the Board of Directors at their Meeting held on Thursday, 20th January, 2011.

Kindly acknowledge receipt.

Thanking You,

Yours faithfully,
For **AJANTA PHARMA LIMITED**


NIKHIL BHATT

G.M. Legal &
Company Secretary

Encl.: a/a

c.c. : National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051.

ajanta pharma limited

Regd. Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67

Stand Alone Financial Results for the quarter ended 31st December, 2010

Particulars	3 months ended		9 months ended		Rupees Lakhs
	31/12/2010	31/12/2009	31/12/2010	31/12/2009	Year Ended 31/03/2010
	Unaudited		Unaudited		Audited
1. Net Sales/Income from Operations	12,050.50	9,465.86	33,129.79	27,378.22	38,166.85
2. Expenditure					
a. (Increase)/decrease in stock in trade and work in progress	1,993.02	629.30	685.01	268.67	1,630.53
b. Consumption of raw & packing materials	2,871.62	2,544.27	10,332.50	7,869.83	11,227.29
c. Purchase of traded goods	578.44	477.98	1,699.16	1,675.20	2,058.34
d. Employees cost	1,475.23	1,141.04	4,196.13	3,297.53	4,452.08
e. Depreciation	622.17	478.02	1,724.25	1,358.11	1,975.56
f. Research & Development Expenses	765.91	422.95	1,782.04	1,501.56	2,026.45
g. Other expenditure	2,087.01	2,510.85	8,278.20	7,735.61	9,650.55
h. Total	10,393.40	8,204.41	28,697.29	23,706.51	33,020.80
3. Profit from operations before Other Income, Interest & Exceptional Items	1,657.10	1,261.45	4,432.50	3,671.71	5,146.05
4. Other Income	68.20	29.34	124.72	64.09	127.35
5. Profit before Interest & Exceptional items	1,725.30	1,290.79	4,557.22	3,735.80	5,273.40
6. Interest	345.93	428.61	1,216.26	1,523.48	1,907.29
7. Profit after Interest but before Exceptional Items	1,379.37	862.18	3,340.96	2,212.32	3,366.11
8. Exceptional items	-	-	-	-	-
9. Profit from Ordinary Activities before tax	1,379.37	862.18	3,340.96	2,212.32	3,366.11
10. Tax Expense	184.51	92.87	443.06	362.59	512.34
11. Net Profit from Ordinary Activities after tax	1,194.86	769.31	2,897.90	1,849.73	2,853.77
12. Extraordinary items (net of tax expense)	-	-	-	-	-
13. Net Profit for the period	1,194.86	769.31	2,897.90	1,849.73	2,853.77
14. Paid-up Equity Share Capital (Face value of Rs. 10/- each)	1,179.61	1,179.61	1,179.61	1,179.61	1,179.61
15. Reserve excluding Revaluation Reserve	NA	NA	NA	NA	16,411.07
16. Earnings Per Share (EPS) Basic and diluted (not annualised) - Rs.	10.21	6.57	24.75	15.80	24.37
17. Public Shareholding					
- Number of shares	3,884,879	3,884,879	3,884,879	3,884,879	3,884,879
- Percentage of shareholding	33.18%	33.18%	33.18%	33.18%	33.18%
18. Promoters and promoter group shareholding					
a) Pledged/Encumbered					
- Number of shares	200,000	1,695,000	200,000	1,695,000	200,000
- Percentage of total promoter's holding	2.56%	21.67%	2.56%	21.67%	2.56%
- Percentage of total share capital of company	1.71%	14.48%	1.71%	14.48%	1.71%
b) Non-encumbered					
- Number of shares	7,623,621	6,128,621	7,623,621	6,128,621	7,623,621
- Percentage of total promoter's holding	97.44%	78.33%	97.44%	78.33%	97.44%
- Percentage of total share capital of company	65.11%	52.34%	65.11%	52.34%	65.11%

Notes :

- Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 20th January, 2011.
- Statutory Auditors have carried out Limited Review of the above results.
- The company has one segment of activity namely, pharmaceuticals.
- Investor's Complaints status - Opening - 0, Received - 4, Resolved - 4, Closing - 0.
- Previous period's figures have been regrouped wherever necessary.

Mumbai, 20th January, 2011



By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director